item management s discussion and analysis of financial condition and results of operations management s discussion and analysis of financial condition and results of operations should be read in conjunction with the accompanying consolidated financial statements 
the information contained in this discussion  other than historical information  consists of forward looking statements that involve risks and uncertainties that could cause actual results to differ materially from those described in such statements 
such statements regarding the timing of acquiring and developing new products  of bringing them on line and of deriving revenues and profits from them  as well as the effects of those revenues and profits on the company s margins and financial position  is uncertain because many of the factors affecting the timing of those items are beyond the company s control 
results of operations the company s revenues are derived from sales of diagnostic and therapeutic pharmaceuticals by the ophthalmic and injectable divisions  from sales of surgical instruments and related products by the ophthalmic division and from sales of contract manufacturing services by the injectable division 
the following table sets forth the percentage relationships that certain items from the company s consolidated statements of income bear to revenues for the year ended december   the six months ended december  and and the years ended june  and six months year ended ended december  december  years ended june  revenues ophthalmic injectable total revenues gross profit selling  general and administrative expenses research and development expenses operating income net income comparison of twelve months ended december  and june  net sales increased for the year ended december  compared to the year ended june  ophthalmic segment sales increased  primarily due to strong performance in the diagnostic and therapeutic product lines 
the acquisition of icg from becton dickinson in april and the introduction of the company s generic version of timolol maleate also contributed to the sales increase 
injectable segment sales increased  primarily due to penetration into the hospital market and strong performance in rheumatology and antidote products  including bal in oil  acquired from becton dickinson in april injectable segment sales also benefited from a continuing shortage of certain distributed products 
division management expects the shortages and resultant sales increases to continue through the first quarter of management continuously evaluates opportunities for acquisition of additional products  and expects such acquisitions to continue in consolidated gross profit increased for the year  with gross margins increasing from to 
the increase in gross margins was caused by product acquisitions  a shift in ophthalmic sales mix to higher margin products and the injectable division s re engineering of production processes to reduce costs of manufacturing 
margins on the company s generic version of timolol maleate have declined at a faster than anticipated rate  due to the large number of competitors offering the product 
management expects prices on this product to stabilize in selling  general and administrative expenses sg a increased  reflecting increased marketing and promotional activities in the ophthalmic segment  provisions for employee performance bonuses and expenses associated with the new corporate office facility 
management expects the growth in sg a expenses in the ophthalmic division to taper off now that the new management team is essentially in place 
sg a spending in the injectable division will increase as it builds its marketing and promotional functions 
research and development expenses r d increased  reflecting a greater number of products under development 
actual spending on r d for the year included approximately  pre funded by pfizer for clinical development of piroxicam 
the pre funded development reserve was exhausted during additional spending for data analysis and development of the nda filing will be reflected in r d expenses 
management expects total r d spending to continue to increase as additional products are brought under development 
during  the company recorded  in charges related to the relocation of the ophthalmic division and executive offices from abita springs  louisiana to the chicago area 
the charges primarily relate to severance and retention bonus payments as well as a write down of the abita springs facility and equipment to net realizable value 
during the year ended june   the company recorded  in charges related to legal  accounting and severance costs associated with the acquisition of prl 
interest expense increased  reflecting higher average outstanding debt balances 
interest income declined due to the liquidation of investments of piroxicam development funds to finance clinical trials 
net income for was  or per diluted share compared to  or per diluted share for the year ended june  the increase in earnings resulted from the above mentioned items 
in june  the financial accounting standards board issued statement of financial accounting standards sfas no 
 reporting comprehensive income  and sfas no 
 disclosures about segments of an enterprise and related information 
see note s to consolidated financial statements 
comparison of six months ended december  and net sales declined for the six months ended december  as compared to the same period in ophthalmic segment sales declined  primarily due to the company s decision to discontinue its practice of granting wholesaler discounts at the end of each quarter 
injectable segment sales increased  primarily due to the acquisition of two anesthesia products from janssen pharmaceutica  inc in july consolidated gross profit declined compared to the prior year period  with gross margins declining from to 
the decline can be attributed to underabsorption of plant overhead expenses caused by decreased unit sales volume in contract manufacturing services 
selling  general and administrative expenses increased over the prior year period  primarily due to increased marketing and promotional activities in the ophthalmic segment 
research and development expenses increased  reflecting an increased number of products in development 
interest and other income expense increased due to increased interest expense on higher average outstanding debt balances 
net income for the period was  or per diluted share compared with  or per diluted share in the prior year period 
the decline is primarily due to the underabsorption of manufacturing overhead expenses and the increase in research and development expenditures 
comparison of twelve months ended june  and consolidated net sales declined for the year ended june  compared to the previous year 
ophthalmic segment sales declined  primarily due to the loss of sales of the segment s best selling allergy product  which was converted to over the counter status in october  and to the company s decision to discontinue its practice of granting wholesaler discounts at the end of each quarter 
injectable segment sales declined  primarily due to loss of contract manufacturing customers which resulted in a reduction in manufacturing unit volume 
consolidated gross profit declined compared to the prior year period  with gross margins declining from to 
the decline can be attributed to price pressure on generic pharmaceuticals and underabsorption of manufacturing overhead due to low unit sales volume 
selling  general and administrative expenses declined over the prior year period  primarily due to cost cutting activities in the ophthalmic segment in response to sales declines 
research and development expenses increased  reflecting an increased number of ophthalmic generic products in development 
the company incurred legal  accounting and severance costs of  in associated with the acquisition of prl 
interest expense increased  due to borrowings for the construction projects at taylor s facilities in decatur 
in  other expense included a  charge for decline in market value of an equity investment 
the company s net income for the period was  or per diluted share compared with  or per diluted share in the prior year period 
the decline is primarily due to the decline in sales  underabsorption of manufacturing overhead expenses  increased research and development expenditures and costs related to the acquisition of prl 
financial condition and liquidity as of december   the company had cash and cash equivalents of  working capital at that date was  versus  at december  the company manages its cash balances to minimize interest expense on its line of credit borrowing 
at december   the company had million available under its revolving credit facility 
during the year ended december   the company generated sufficient cash from operations to finance its working capital requirements  primarily an increase in accounts receivable and inventories related to increased sales volume 
management anticipates additional investment in working capital to finance continued sales growth 
investing activities  which include purchases of property  plant and equipment as well as the purchase of product related intangible assets  required  in cash 
investing activities were funded through issuance of long term debt of  short term borrowings of  and proceeds from the sale of stock of  as indicated in note i to the consolidated financial statements  in the company entered into a million revolving credit arrangement  subject to certain financial covenants 
management believes that cash flow from operations  in conjunction with borrowing availability under its credit facility  will be sufficient to meet the cash needs of the business for the immediate future  but additional long term financing may be needed to meet the company s product acquisition plans 
there are no guarantees that such financing will be available or available at an acceptable cost 
on january   the company announced the purchase of the nda  trademark and us trade name rights to paremyd  a topical mydriatic combination product  from allergan 
paremyd has been off the market for all of due to a raw material shortage 
the company will  with allergan s assistance  move quickly to obtain fda approval to manufacture the product at taylor 
the total purchase price was  with  paid in cash upon closing and  payable upon receipt of an approved supplement from the fda or twelve months from closing  whichever is sooner 
on january   the company announced the purchase of two branded injectable products  sufenta and alfenta  from janssen pharmaceutica  inc the products are injectable opioid analgesics indicated for use in the induction and maintenance of general anesthesia 
both are nda products  and alfenta remains covered under patent 
the total purchase price was  with  paid in cash upon closing and two additional payments of  payable on the next anniversary of the closing date and on december   respectively 
the second two payments are secured by irrevocable bank letters of credit  which are issued under the revolving credit facility see note i of notes to consolidated financial statements 
year issues the company utilizes commercially available software to store and process its business information and transactions 
the company s plans to become year compliant involve upgrading the server software of its injectable division and completing the installation of year compliant financial software in the ophthalmic division 
both divisions expect to be fully compliant by the end of the cost of this software upgrade and conversion is estimated at less than  of which approximately  was incurred in selected quarterly data in thousands  except per share amounts net income loss net gross per share per share sales profit amount basic diluted year ended december  st quarter   nd quarter   rd quarter   th quarter   six months ended december  st quarter   nd quarter   fiscal year ended june  st quarter   nd quarter   rd quarter   th quarter   
